Up-regulation of IGF binding protein-1 as an anticarcinogenic strategy: Relevance to caloric restriction, exercise, and insulin sensitivity

Medical Hypotheses

Volumn 48, Issue 4, 1997, Pages 297-308

  McCarty, M F ^a  

^a Nutrition 21 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; SOMATOMEDIN BINDING PROTEIN 1;

ARTICLE; ATHEROSCLEROSIS; CALORIC RESTRICTION; CANCER RISK; DISEASE ASSOCIATION; DOWN REGULATION; EXERCISE; HUMAN; HYPERINSULINEMIA; HYPERPLASIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER METABOLISM; MITOSIS RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION;

ANIMALIA;

EID: 0030906744     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(97)90098-0     Document Type: Article

References (153)

1. Combs G F Jr, Clark L C. Can dietary selenium modify cancer risk? Nutr Rev 1985; 43: 325-331.
2. Yu S-Y, Chu Y-J, Gong X-L et al. Regional variation of cancer mortality incidence and its relation to selenium levels in China. Biol Trace Elem Res 1985; 7: 21-29.
3. Yu S-Y, Zhu Y-J, Li W-G et al. A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in China. Biol Trace Elem Res 1991; 29: 289-294.
4. Simic M G. Mechanisms of inhibition of free-radical processes in mutagenesis and carcinogenesis. Mutation Res 1988; 202: 377-386.
5. Katiyar S K, Agarwal R, Mukhtar H. Green tea in chemoprevention of cancer. Comp Ther 1992; 18: 3-8.
6. Talalay P. Mechanisms of induction of enzymes that protect against chemical carcinogenesis. Adv Enzyme Regulation 1989; 28: 237-250.
7. Stoewsand G S, Anderson J L, Munson L. Protective effect of dietary brussels sprouts against mammary carcinogenesis in Sprague-Dawley rats. Cancer Lett 1988; 39: 199-207.
8. Bresnick E, Birt D F, Wolterman K et al. Reduction in mammary tumorigenesis in the rat by cabbage and cabbage residue. Carcinogenesis 1990; 11: 1159-1163.
9. Mello-Filho A C, Meneghini R. Iron is the intracellular metal involved in the production of DNA damage by oxygen radicals. Mutation Res 1991; 251: 109-113.
10. Stevens R G, Jones D Y, Micozzi M S, Taylor R P. Body iron stores and the risk of cancer. N Engl J Med 1988; 319: 1047-1052.
11. Stevens R G, Graubard B I, Micozzi M S et al. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 1994; 56: 364-369.
12. McCarty M F. Natural anti-mutagenic agents may prolong efficacy of HIV drug therapy. Med Hypotheses 1997; 48: 215-220.
13. Wortzman M S, Besbris H J, Cohen A M. Effect of dietary selenium on the interaction between 2-acetylaminofluorene and rat liver DNA in vivo. Cancer Res 1980; 40: 2670-2676.
14. Lawson T, Birt D F. Enhancement of the repair of carcinogen-induced DNA damage in the hamster pancreas by dietary selenium. Chem-Biol Interact 1983; 45: 95-104.
15. Lanfear J, Fleming J, Wu L et al. The selenium metabolite selenodiglutathione induces p53 and apoptosis: relevance to the chemopreventive effects of selenium? Carcinogenesis 1994; 15: 1387-1392.
16. Preston-Martin S, Pike M C, Ross R K et al. Increased cell division as a cause of human cancer. Cancer Res 1990; 50: 7415-7421.
17. Albanes D, Winick M. Are cell number and cell proliferation risk factors for cancer? J Natl Cancer Inst 1988; 80: 772-775.
18. Koga A, Kimura S. Influence of restricted diet on the cell cycle in the crypt of mouse small intestine. J Nutr Sci Vitaminol 1980; 26: 33-38.
19. Lok E, Scott F W, Mongeau R et al. Calorie restriction and cellular proliferation in various tissues of the female Swiss Webster mouse. Cancer Lett 1990; 51: 67-73.
20. Parr T. Insulin exposure controls the rate of mammalian aging. Mech Ageing Dev 1996, in press.
21. Lewitt M S, Baxter R C. Insulin-like growth factor-binding protein-1: a role in glucose counterregulation? Mol Cell Endocrinol 1991; 79: C147-C152.
22. Lee P D K, Conover C A, Powell D R. Regulation and function of insulin-like growth factor-binding protein-1. Proc Soc Exp Biol Med 1993; 204: 4-29.
23. Baxter R C. Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res 1994; 42: 140-144.
24. Yeoh S I, Baxter R C. Metabolic regulation of the growth hormone independent insulin-like growth factor binding protein in human plasma. Acta Endocrinol 1988; 119: 465-473.
25. Busby W H, Snyder D K, Clemmons D R. Radioimmunoassay of a 26 000-Dalton plasma insulin-like growth factor-binding protein: control by nutritional variables. J Clin Endocrinol Metab 1988; 67: 1225-1230.
26. Donovan S M, Atilano L C, Hintz R L et al. Differential regulation of the insulin-like growth factors (IGF-I and -II) and IGF binding proteins during malnutrition in the neonatal rat. Endocrinology 1991; 129: 149-157.
27. Ross M H, Bras G. Lasting influence of early caloric restriction on prevalence of neoplasms in the rat. J Natl Cancer Inst 1971; 47: 1095-1113.
28. Weindruch R, Walford R L. Dietary restriction in mice beginning at 1 year of age: effect on life-span and spontaneous cancer incidence. Science 1982; 215: 1415-1418.
29. Albanes D. Total calories, body weight, and tumor incidence in mice. Cancer Res 1987; 47: 1987-1992.
30. Pledger W J, Stiles C D, Antoniades H N, Scher C D. An ordered sequence of events is required before BALB/c-3T3 cells become committed to DNA synthesis. Proc Natl Acad Sci 1978; 75: 2839-2843.
31. Reiss K, Porcu P, Sell C et al. The insulin-like growth factor 1 receptor is required for the proliferation of hemopoietic cells. Oncogene 1992; 7: 2243-2248.
32. Baserga R, Rubin R. Cell cycle and growth control. Crit Rev Eukaryotic Gene Expression 1993; 3: 47-61.
33. Baserga R, Porcu P, Rubini M, Sell C. Cell cycle control by the IGF-1 receptor and its ligands. In: LeRoith D, Raisada M K, eds. Current Directions in Insulin-Like Growth Factor Research. New York: Plenum Press, 1994: 105-112.
34. Liu J-P, Baker J, Perkins A S et al. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igfr). Cell 1993; 75: 59-72.
35. Baker J, Liu J-P, Robertson E J, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993; 75: 73-82.
36. Goldring M B, Goldring S R. Cytokines and cell growth control. Crit Rev Eukaryotic Gene Expression 1991; 1: 301-326.
37. Czech M. Signal transduction by the insulin-like growth factors. Cell 1989; 59: 235-238.
38. Lahm H, Amstad P, Wyniger J et al. Blockade of the insulin-like growth-factor-I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-II-mediated autocrine loop. Int J Cancer 1994; 58: 452-459.
39. Baxter R C, Cowell C T. Diurnal rhythm of growth hormone-independent binding protein for insulin-like growth factors in human plasma. J Clin Endocrinol Metab 1987; 65: 432-440.
40. Suikkari A-M, Koivisto V A, Koistinen R et al. Dose-response characteristics for suppression of low molecular weight plasma insulin-like growth factor-binding protein by insulin. J Clin Endocrinol Metab 1989; 68: 135-140.
41. Suikkari A-M, Sane T, Seppälä M et al. Prolonged exercise increases serum insulin-like growth factor-binding protein concentrations. J Clin Endocrinol Metab 1989; 68: 141-144.
42. Snyder D K, Clemmons D R. Insulin-dependent regulation of insulin-like growth factor-binding protein-1. J Clin Endocrinol Metab 1990; 71: 1632-1636.
43. Binoux M, Schimpff R M, Donnadieu M. Serum somatomedin activity depressed after glucagon administration in man. J Clin Endocrinol Metab 1977; 44: 1006-1009.
44. Suikkari A-M, Koivisto V A, Rutanen E-M et al. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab 1988; 66: 266-272.
45. Lewitt M S, Baxter R C. Regulation of growth hormone-independent insulin-like growth factor-binding protein (BP-28) in cultured human fetal liver explants. J Clin Endocrinol Metab 1989; 69: 246-252.
46. Conover C A, Lee P K D, Kanaley J A et al. Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans. J Clin Endocrinol Metab 1992; 74: 1355-1360.
47. Suwanichkul A, DePaolis L A, Lee P D K, Powell D R. Identification of a promoter element which participates in cAMP-stimulated expression of human insulin-like growth factor-binding protein-1. J Biol Chem 1993; 268: 9730-9736.
48. Exton J H, Park C R. Interaction of insulin and glucagon in the control of liver metabolism. In: Geiger S R, ed. Handbook of Physiology, Vol 1. Washington DC: American Physiological Society, 1972: 437-455.
49. Brismar K, Grill V, Efendic S, Hall K. The insulin-like growth factor binding protein-1 in low and high insulin responders before and during dexamethasone treatment. Metabolism 1991; 40: 728-732.
50. Lewitt M S, Baxter R C. Inhibitors of glucose uptake stimulate the production of insulin-like growth factor-binding protein (IGFBP-1) by human fetal liver. Endocrinology 1990; 126: 1527-1533.
51. Lewitt M S, Denyer G S, Cooney G J, Baxter R C. Insulin-like growth factor-binding protein-1 modulates blood gucose levels. Endocrinology 1991; 129: 2254-2256.
52. Taylor A M, Dunger D B, Preece M A et al. The growth hormone independent insulin-like growth factor-I binding protein BP-28 is associated with serum insulin-like growth factor-I inhibitory bioactivity in adolescent insulin-dependent diabetics. Clin Endocrinol 1990; 32: 229-239.
53. Graubert M D, Goldstein S, Phillips L S. Nutrition and somatomedin. XXVII. Total and free IGF-I and IGF binding proteins in rats with streptozocin-induced diabetes. Diabetes 1991; 40: 959-965.
54. Rutanen E-M, Pekonen F, Mäkinen T. Soluble 34K binding protein inhibits the binding of insulin-like growth factor I to its cell receptors in human secretory phase endometrium: evidence for autocrine/paracrine regulation of growth factor action. J Clin Endocrinol Metab 1988; 66: 173-180.
55. Ritvos O, Ranta T, Jalkanen J et al. Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-I in cultured choriocarcinoma cells. Endocrinology 1988; 122: 2150-2157.
56. Burch W M, Correa J, Shively J E, Powell D R. The 25-kilodalton insulin-like growth factor (IGF)-binding protein inhibits both basal and IGF-I-mediated growth of chick embryo pelvic cartilage in vitro. J Clin Endocrinol Metab 1990; 70: 173-180.
57. Liu L, Brinkman A, Blat C, Harel L. IGFBP-1, an insulin like growth factor binding protein, is a cell growth inhibitor. Biochem Biophys Res Comm 1991; 174: 673-679.
58. Yee D, Jackson J G, Kozelsky T W, Figueroa J A. Insulin-like growth factor binding protein 1 expression inhibits insulin-like growth factor I action in MCF-7 breast cancer cells. Cell Growth Diff 1994; 5: 73-77.
59. Cleramons D R, Gardner L I. A factor contained in plasma is required for IGF binding protein-1 to potentiate the effect of IGF-I on smooth muscle cell DNA synthesis. J Cell Physiol 1990; 145: 129-135.
60. Koistinen R, Itkonen O, Selenius P, Seppälä M. Insulin-like growth factor-binding protein-1 inhibits binding of IGF-I on fetal skin fibroblasts but stimulates their DNA synthesis. Biochem Biophys Res Comm 1990; 173: 408-415.
61. McCarty M F. Chromium and other insulin sensitizers may enhance glucagon secretion: implications for hypoglycemia and weight control. Med Hypotheses 1996; 46: 77-80.
62. Ward T L, Berrio L F, Southern L L et al. In-vivo and in-vitro evaluation of chromium tripicolinate on insulin binding in pig liver cell plasma membranes. FASEB J 1994; 8: A194.
63. Yang W Z, Mowat D N. Effects of supplemental chromium on gluconeogenesis in lactating cows following propionate infusion. J Dairy Sci 1994; 77(Suppl. 1): Abstr 707.
64. Evans G W, Meyer L K. Life span is increased in rats supplemented with a chromium-pyridine 2 carboxylate complex. Adv Sci Res 1994; 1: 19-23.
65. Mertz W. Chromium occurrence and function in biological systems. Physiol Rev 1969; 49: 163-239.
66. Holloszy J O, Smith E K, Vining M, Adams S. Effect of voluntary exercise on longevity of rats. J Appl Physiol 1985; 59: 826-831.
67. Holloszy J O. Exercise and longevity: studies on rats. J Gerontol 1988; 43: B149-B151.
68. Dilman V M. Metabolic immunodepression which increases the risk of cancer (hypothesis). Lancet 1977; ii: 1207-1209.
69. Dilman V, Dean W. In: Fowkes S W, ed. The Neuroendocrine Theory of Aging and Degenerative Disease. Pensacola, FL: The Center for Bio-Gerontology, 1992.
70. Albanes D. Caloric intake, body weight, and cancer: a review. Nutr Cancer 1987; 9: 199-217.
71. Garrison R J, Feinleib M, Castelli W P. Cigarette smoking as a confounder of the relationship between relative weight and long-term mortality. J Am Med Assoc 1983; 249: 2199-2203.
72. Manson J E, Stampfer M J, Hennekins C H, Willett W C. Body weight and longevity. A reassessment. J Am Med Assoc 1987; 257: 353-358.
73. Ballard-Barbash R, Schatzkin A, Carter C L et al. Body fat distribution and breast cancer in the Framingham study. J Natl Cancer Inst 1990; 82: 286-290.
74. Folsom A R, Kaye S A, Prineas R J et al. Increased incidence of carcinoma of the breast associated with abdominal adiposity in postmenopausal women. Am J Epidemiol 1990; 131: 794-803.
75. Schapira D V, Kumar N B, Lyman G H, Cox C E. Abdominal obesity and breast cancer risk. Ann Int Med 1990; 112: 182-186.
76. Levine W, Dyer A R, Shekelle R B et al. Post-load plasma glucose and cancer mortality in middle-aged men and women: 12-year follow-up findings of the Chicago Heart Association Detection Project in Industry. Am J Epidemiol 1990; 131: 254-262.
77. Smith G D, Egger M, Shipley M J, Marmot M G. Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. Am J Epidemiol 1992; 136: 1110-1114.
78. O'Mara B A, Byers T, Schoenfeld E. Diabetes mellitus and cancer risk: a multisite case-control study. J Chron Dis 1985; 38: 435-441.
79. Cullen K, Stenhouse N S, Wearne K L, Welborn T A. Multiple regression analysis of risk factors for cardiovascular disease and cancer mortality in Busselton, Western Australia - 13-year study. Chron Dis 1983; 36: 371-377.
80. Ferrannini E, Buzzigoli G, Bonadonna R et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-357.
81. Dyer A R, Berkson D M, Stamler J et al. High blood-pressure: a risk factor for cancer mortality? Lancet 1975; i: 1051-1056.
82. Berstein L M. Newborn macrosomy and cancer. Adv Cancer Res 1988; 50: 231-261.
83. Hall K, Hansson U, Lundin G et al. Serum levels of somatomedins and somatomedin-binding protein in pregnant women with type I or gestational diabetes and their infants. J Clin Endocrinol Metab 1986; 63: 1300-1306.
84. Frisch R E, Wyshak G, Albright N L et al. Lower lifetime occurrence of breast cancer and cancers of the reproductive system among former college athletes. Am J Clin Nutr 1987; 45: 328-335.
85. Frisch R E, Wyshak G, Albright N L et al. Lower prevalence of non-reproductive system cancers among female former college athletes. Med Sci Sports Exerc 1989; 21: 250-253.
86. Blair S N, Kohl H W III, Paffenbarger R S Jr et al. Physical fitness and all-cause mortality. A prospective study of healthy men and women. J Am Med Assoc 1989; 262: 2395-2401.
87. Albanes D, Blair A, Taylor P R. Physical activity and risk of cancer in the NHANES I population. Am J Public Health 1989; 79: 744-750.
88. Lee I-M, Paffenbarger R S Jr, Hsieh C-C. Physical activity and risk of prostatic cancer among college alumni. Am J Epidemiol 1992; 135: 169-179.
89. Sternfeld B. Cancer and the protective effect of physical activity: the epidemiological evidence. Med Sci Sports Exerc 1992; 24: 1195-1209.
90. Tonino R P. Effect of physical training on the insulin resistance of aging. Am J Physiol 1989; 256: E352-E356.
91. Masoro E J, McCarter R J M, Katz M S, McMahan C A. Dietary restriction alters characteristics of glucose fuel use. J Gerontol Biol Sci 1992; 47: B202-B208.
92. Thissen J-P, Ketelslegers J-M, Underwood L E. Nutritional regulation of the insulin-like growth factors. Endocrine Rev 1994; 15: 80-101.
93. McCarty M F. Promotion of hepatic lipid oxidation and gluconeogenesis as a strategy for appetite control. Med Hypotheses 1994; 42: 215-225.
94. McCarty M F. Inhibition of citrate lyase may aid aerobic endurance. Med Hypotheses 1995; 45: 247-254.
95. Rudman D, Feller A G, Nagraj H S et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323: 1-6.
96. Ron E, Gridley G, Hrubec Z et al. Acromegaly and gastrointestinal cancer. Cancer 1991; 68: 1673-1677.
97. Bratusch-Marrain P R, Smith D, DeFronzo R A. The effect of growth hormone on glucose metabolism and insulin secretion in man. J Clin Endocrinol Metab 1982; 55: 973-982.
98. Ezzat S, Melmed S. Clinical review 18. Are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab 1991; 72: 245-249.
99. Moon H D, Simpson M E, Li C H, Evans H M. Neoplasms in rats treated with pituitary growth hormone. I. Pulmonary and lymphatic tissues. Cancer Res 1950; 10: 297-308.
100. Akaza H, Matsuki K, Matsushima H et al. Stimulatory effects of growth hormone on rat bladder carcinogenesis. Cancer 1991; 68: 2418-2421.
101. Moon H D, Li C H, Simpson M E. Effect of pituitary hormones on carcinogenesis with 9,10-dimethyl-1,2-dibenzanthracene in hypophysectomized rats. Cancer Res 1956; 16: 111-116.
102. Bentley H P, Hughes E R, Peterson R D A. Effect of hypophysectomy on a virus-induced T-cell leukemia. Nature 1974; 252: 747-748.
103. Rogers P C, Komp D, Sabio H, Rogol A. Possible effects of growth hormone on development of acute lymphoblastic leukemia. Lancet 1977; ii: 434-435
104. Kiddy D S, Hamilton-Fairley D, Seppälä M et al. Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin-like growth factor-I. Clin Endocrinol 1989; 31: 757-763.
105. Plymate S R, Matej L A, Jones R E, Friedl K E. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1988; 67: 460-464.
106. Singh A, Hamilton-Fairley D, Koistinen R et al. Effect of insulin-like growth factor-type I (IGP-I) and insulin on the secretion of sex hormone binding globulin and IGF-I binding protein (IBP-I) by human hepatoma cells. J Endocrinol 1990; 124: R1-R3.
107. Holly J M P, Smith C P, Dunger D B et al. Relationship between the pubertal fall in sex hormone binding globulin and insulin-like growth factor binding protein-I. A synchronized approach to pubertal development. Clin Endocrinol 1989; 31: 277-284.
108. Reed M J, Cheng R W, Simmonds M et al. Dietary lipids: an additional regulator of plasma levels of sex hormone binding globulin. J Clin Endocrinol Metab 1987; 64: 1083-1085.
109. Fukagawa N K, Anderson J W, Hageman G et al. High-carbohydrate, high-fiber diets increase peripheral insulin sensitivity in healthy young and old adults. Am J Clin Nutr 1990; 52: 524-528.
110. Barnard R J, Ugianskis E J, Martin D A, Inkeles S B. Role of diet and exercise in the management of hyperinsulinemia and associated atherosclerotic risk factors. Am J Cardiol 1992; 69: 440-444.
111. Carroll K K. Experimental studies on dietary fat and cancer in relation to epidemiological data. In: Ip C, Birt D, Rogers A E, Mettlin C, eds. Dietary Fat and Cancer. New York: Alan R. Liss, 1986: 231-248.
112. Daughaday W H. Editorial: the possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology 1990; 127: 1-4.
113. Macaulay V M. Insulin-like growth factors and cancer. Br J Cancer 1992; 65: 311-320.
114. Prager D, Li H-L, Asa S, Melmed S. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci 1994; 91: 2181-2185.
115. LeRoith D, Baserga R, Helman L, Roberts C T Jr. Insulin-like growth factors and cancer. Ann Intern Med 1995; 122: 54-59.
116. Figueroa J A, Sharma J, Jackson J G et al. Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells. J Cell Physiol 1993; 157: 229-236.
117. Schally A V. Oncological applications of somatostatin analogues. Cancer Res 1988; 48: 6977-6985.
118. Glauber H, Wallace P, Griver K, Brechtel G. Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Intern Med 1988; 108: 663-668.
119. Stacpoole P W, Alig J, Ammon L, Crockett S E. Dose-response effects of dietary marine oil on carbohydrate and lipid metabolism in normal subjects and patients with hypertriglyceridemia. Metabolism 1989; 38: 946-956.
120. Kasim S E. Dietary marine fish oils and insulin action in type 2 diabetes. Ann NY Acad Sci 1993; 683: 250-257.
121. McCarty M F. Fish oil may impede tumour angiogenesis and invasiveness by down-regulating protein kinase C and modulating eicosanoid production. Med Hypotheses 1996; 46: 107-115.
122. Colletti R B, Roberts J D, Devlin J T, Copeland K C. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res 1989; 49: 1882-1884.
123. Lønning P E, Hall K, Aakvaag A, Lien E A. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 1992; 52: 4719-4723.
124. Lahti E I, Knip M, Laatikainen T J. Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen. Cancer 1994; 74: 618-624.
125. Farinati F, DeMaria N, Fornasiero A et al. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Digest Dis Sci 1992; 37: 659-662.
126. Roig L M V, Lotfi H, Olcese J E et al. Effects of short-term tamoxifen administration in patients with invasive cervical carcinoma. Anticancer Res 1993; 13: 2457-2464.
127. McClay E F, McClay M E T. Tamoxifen: is it useful in the treatment of patients with metastatic melanoma? J Clin Oncol 1994; 12: 617-626.
128. Suikkari A-M, Tiitinen A, Stenman U-H et al. Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease. Fertil Steril 1991; 55: 895-899.
129. Martikainen H, Koistinen R, Seppälä M. The effect of estrogen level on glucose-induced changes in serum insulin-like growth factor binding protein-1 concentration. Fertil Steril 1992; 58: 543-546.
130. Reaven G M. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
131. DeFronzo R A, Ferrannini E. Insulin resistance. A multifaceted syndrome resonsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardio-vascular disease. Diabetes Care 1991; 14: 173-194.
132. Stout R W, Vallance-Owen J. Insulin and atheroma. Lancet 1969; i: 1078-1080.
133. Stout R W. The relationship of abnormal circulating insulin levels to atherosclerosis. Atherosclerosis 1977; 27: 1-13.
134. Taggart H, Stout R W. Control of DNA synthesis in cultured vascular endothelial and smooth muscle cells. Atherosclerosis 1980; 37: 549-557.
135. Stout R W. Insulin and atheroma. 20-yr perspective. Diabetes Care 1990; 13: 631-654.
136. McCarty M F. Hemostatic concomitants of syndrome X. Med Hypotheses 1995; 44: 175-193.
137. King G L, Kahn C R, Rechler M M, Nissley S P. Direct demonstration of separate receptors for growth and metabolic activities of insulin and multiplication-stimulating activity (an insulinlike growth factor) using antibodies to the insulin receptor. J Clin Invest 1980; 66: 130-140.
138. Banskota N K, Taub R, Zellner K et al. Characterization of induction of protooncogene c-myc and cellular growth in human vascular smooth muscle cells by insulin and IGF-I. Diabetes 1989; 38: 123-129.
139. Taskinen M-R, Kuusi T, Helve E et al. Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 1988; 8: 168-177.
140. McCarty M F. Reduction of free fatty acids may ameliorate risk factors associated with abdominal obesity. Med Hypotheses 1995; 44: 278-286.
141. Anderson E A, Mark A L. The vasodilator action of insulin. Implications for the insulin hypothesis of hypertension. Hypertension 1993; 21: 136-141.
142. Kim Y-C, Zemel M B. Insulin increases vascular smooth muscle recovery from intracellular calcium loads. Hypertension 1993; 22: 74-77.
143. Feldman R D, Bierbrier G S. Insulin-mediated vasodilation: impairment with increased blood pressure and body mass. Lancet 1993; 342: 707-709.
144. McCarty M F. Insulin resistance - not hyperinsulinemia - is pathogenic in essential hypertension. Med Hypotheses 1994; 42: 226-236.
145. McCarty M F. Up-regulation of intracellular signalling pathways may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer promotion - the 'PKC syndrome'. Med Hypotheses 1996; 46: 191-221.
146. Meinert C L, Knatterud G L, Prout T E, Klimt C R. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19: 789-830.
147. Armstrong M L, Heistad D D, Megan M B et al. Reversibility of atherosclerosis. In: Frohlich E D, Brest A N, eds. Preventive Aspects of Coronary Heart Disease. Philadelphia, PA: FA Davis Company, 1990; 113: 126.
148. Landon J C, Wynn V, Samols E. The effects of anabolic steroids on blood sugar and plasma insulin levels in man. Metabolism 1963; 12: 924-930.
149. Nobels F, Dewailly D. Puberty and polycystic ovarian syndrome: the insulin/insulin-like growth factor I hypothesis. Fertil Steril 1992; 58: 655-666.
150. Barbieri R L. Hyperandrogenism, insulin resistance and acanthosis nigricans. 10 years of progress. J Reprod Med 1994; 39: 327-336.
151. Cara J F, Rosenfield R L. Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinol 1988; 123: 733-739.
152. Rosen C J, Donahue L R, Hunter S J. Insulin-like growth factors and bone: the osteoporosis connection. Proc Soc Exp Biol Med 1994; 206: 83-102.
153. Hui S L, Epstein S, Johnston C C Jr. A prospective study of bone mass in patients with type I diabetes. J Clin Endocrinol Metab 1985; 60: 74-80.